Paul Rizzoli,Michael J. Marmura,Jennifer Robblee,Jennifer McVige,Sara Sacco,Stephanie J. Nahas,Jessica Ailani,Rosa De Abreu Ferreira,Julia Ma,Jonathan H. Smith,Brett Dabruzzo,Messoud Ashina

Abstract:Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine symptoms, improve function, and enhance quality of life. Atogepant is a migraine-specific oral calcitonin gene–related peptide receptor antagonist that is indicated for the preventive treatment of migraine in adults. This analysis evaluated the safety and tolerability profile of atogepant for the preventive treatment of migraine, including adverse events (AEs) of interest, such as constipation, nausea, hepatic safety, weight changes, and cardiac disorders.

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials